Original Research: A sero-survey to identify the window of vulnerability to measles in infants As infants lose maternal measles antibodies (MMAs), they experience periods when their antibody levels are insufficient to protect them against measles. A prospective study was carried out at the University of Maiduguri Teaching Hospital. Sera collected from neonates at birth, and at six weeks, three months, six months and nine months of age, were analysed for MMAs by enzyme-linked immunosorbent assay. Seventy-seven neonates were enrolled. Of these, 73 (94.8%) had protective MMAs at birth. This figure declined to 36 (46.8%), 28 (36.4%), 13 (16.9%) and 4 (5.2%) at six weeks, three months, six months and nine months of age (χ 2 = 154.264, p-value = 0.000). Protective MMAs at birth waned rapidly, resulting in an early window of vulnerability to measles by the age of six months. Protecting infants with early measles immunisation with potent, safe vaccines are recommended.
Introduction
Since the introduction of an inexpensive and highly effective measles vaccine in the 1960s and the global prioritisation of measles control initiatives, the burden of the disease has significantly reduced worldwide. 1 In 1997, there were 36 million cases, and more than one million deaths occurred worldwide, but measles now accounts for an estimated 164 000 deaths per year globally. 2 Yet, it still persists as a public health threat. In Africa, the number of cases increased from 36 000 in 2009 to 172 824 in 2010, and outbreaks were reported in countries with successful measles control programmes. 3 During a two-year study, Ashir et al reported 11.2% cases of measles in Maiduguri, Nigeria in 2009. 4 A notable proportion of measles occurs in infants before the age of nine months, which is the age at which the measles vaccination is currently recommended in most developing countries. 5 The occurrence of measles in these infants results from numerous factors, including the high transmissibility of the measles virus and increasing rates of vaccine refusal because of ignorance and socio-cultural beliefs, especially in developing countries, which deprive children of access to immunisation services. 4, 6 The current measles vaccine does not elicit high antibody levels when administered to infants who are younger than nine months of age. 7 Maternal measles antibodies (MMAs) that are still present in infants could neutralise the measles vaccine, thereby making it ineffective before one year of age. Finally, while MMAs, at adequate levels, can protect infants early in life, multiple factors influence the quantity of measles antibodies that cross the placenta to the foetus. 8
As a result, for several months many infants are vulnerable when their MMAs fall below protective levels against the measles virus. At the same time, these low MMAs may interfere with antibody production in response to the measles vaccine. During this window of vulnerability, young infants may develop severe or fatal measles, if exposed to the measles virus. 9 In the 1990s, vaccination of six-month-old infants with a highdose measles vaccine was explored as a strategy to overcome MMAs and enable successful measles immunisation of infants during this window period. 10 However, excess mortality in female infants, which was believed to be as a result of their low antibody-dependent cellular cytotoxicity response, led to abandonment of that approach. 11, 12 The decision to forsake the use of a high-dose measles vaccine may have been too hasty because excess female mortality in recipients of the high-dose measles vaccine was not a consistent finding. For instance, excess female mortality was not reported in Gambian subjects who received the high-dose measles vaccine. 12 A possible explanation for this finding could be the presence of MMAs in that study population prior to administration of the highdose measles vaccine, as excess mortality was observed in female subjects with undetectable MMAs prior to measles immunisation. 12 Absence of MMAs may result in greater measles virus replication following immunisation, putting these infants at greater risk of events that are associated with immunosuppression. Factors that are associated with low cellular-mediated immune response, namely female sex, high-titre vaccine and early age, are not restricted to measles vaccines alone. These factors have also been associated with lower survival rates in other vaccine-preventable diseases. 11, 12 The primary strategy, now being pursued to control the measles burden in developing countries mostly, is based on mass measles immunisation campaigns that target infants and older children. By drastically diminishing the incidence of measles in a susceptible population, it is hoped that infants will be indirectly protected. An adjunct control strategy aims to immunise infants who are less than six months of age with a new generation of measles vaccine in developing countries. In support of this strategy, the Bill and Melinda Gates Foundation has sponsored initiatives to develop measles vaccines that can be safely administered in early infancy. 13 The new vaccines may supplement what can be accomplished with the current measles vaccines. Information on the prevalence of MMAs at different time intervals in infancy is needed to help to guide the development of these new vaccines.
Method
Our prospective hospital-based cohort study was carried out on newborn infants at the Paediatrics and Obstetrics Units of the University of Maiduguri Teaching Hospital (UMTH), north-eastern Nigeria, between 10 January 2010 and 21 July 2011. The UMTH serves as a referral site for the region and the neighbouring countries of Chad, Cameroon and Niger. Ethical approval was obtained from UMTH's Medical Research and Ethics Committee. Informed consent was also obtained from parents. The subjects were selected using the systematic random sampling method whereby the first of every three newborn infants was selected at the labour ward. Two millilitres of umbilical cord blood were taken from the newborn infants to quantify the MMAs. Subsequently, during each infant's visit at six weeks, three months, six months and nine months of age, 2 ml of venous blood was obtained from the infant to analyse the MMAs. Collected blood samples were centrifuged and the serum was stored at -20°C until the time of assay.
Demographic variables and medical history, including a history of measles, contact with suspected measles and a history of transfused blood, were collected during enrolment and subsequent visits. Samples were assayed individually for MMAs using enzyme-linked immunosorbent assay in accordance with the standardised laboratory procedure to determine the MMAs. 14, 15 The optical densities of reactions in the well plates were read in an automated analyser at 450 nanometre wavelength. MMA titres were obtained by plotting graphs of optical densities against measles immunoglobulin G concentrations. Protective titres for MMAs were defined as levels of MMAs > 12 U/ml and unprotective titres as levels of MMAs ≤ 12 U/ml, 14 similar to that mentioned in a publication by Joshi and Gambhir. 16 Data were analysed using SPSS ® statistical software version 16 (Illinois, Chicago USA). Values were expressed as mean ± standard deviation (SD). The mean coefficients were compared using Student's t-test. The chi-squared (χ 2 ) test was employed where appropriate to determine associations for the qualitative variables. A p-value < 0.05 was considered to be significant based on the sample size estimate of current study subjects. Tables were used for illustrations. Table I shows that a total of 77 infants at birth were followed up to nine months of age. There were 40 male (51.9%) and 37 female (48.1%) infants. This equates to an approximate male to female ratio of 1.1:1. Nine (11.7%) of the newborn infants were preterm, 57 (74%) were full-term and 11 (14.3%) were post-term deliveries, respectively. The majority of the newborn infants (73, 94.8%) had protective MMAs at birth. The mean ± SD of MMAs of the newborn infants at birth was 216.04 ± 72.57 U/ml at 95% confidence interval: 199.57-232.51 U/ml. Table II shows the proportion of MMA levels of the infants at different ages in the follow-up cohort. The number of infants with protective MMAs declined to 36 (46.8%), 28 (36.4%), 13 (16.9%) and 4 (5.2%) at six weeks, three months, six months and nine months of age, respectively. Sixty-four infants (83.1%) had unprotective MMAs at six months of age. The overall decline in the proportion of infants with protective MMAs from birth to nine months of age was significant (p-value = 0.000). The association of mean MMAs from birth up to nine months of age with the gestational age of the newborn infants was insignificant for preterm (p-value = 0.272), full-term (p-value = 0.246) and post-term (p-value = 0.226) deliveries. Similarly, the mean MMAs from birth up to nine months of age had an insignificant association with the gender of the newborn infants for male (p-value = 0.257) and female (p-value = 0.234).
Results

Discussion
Our findings show that the window of vulnerability to measles in infants in Maiduguri begins at six weeks and extends to nine months of age, which is the recommended age for measles vaccination in developing countries. There were significant losses of MMAs at six weeks of age in the current study. This conforms with observations that were made in Ilorin, Nigeria, and with those on Kangaba infants in Mali. 17, 18 However, almost all of the studied infants in Bangladesh had protective levels of MMAs at six weeks of age. 19 This suggests that in the present study, during pregnancy, the mothers may have transferred a lesser, but protective, amount of MMAs via the placenta to their foetuses. Hypergammaglobulinaemia, which reduces the placental transfer of MMAs, could have led to the observed levels of MMAs at six weeks of age in this study. Previous studies have also demonstrated that hypergammaglobulinaemia decreases the placental transfer of MMAs in African mothers, compared to mothers in industrialised countries. 8 Natural infection of mothers with the measles virus, because of the high incidence of measles, was the reason that was advanced for MMAs in infants at six weeks in Bangladesh. 19 In the present study, at three and six months of age, 63.6% and 83.1% of infants had unprotective levels of MMAs. This is similar to observations that were reported in studies on Nigerian and Argentinean subjects. 20, 21 The most likely explanation for this could be the changing epidemiology of measles, such that MMAs identified in infants today are low, compared to those reported in infants decades ago. 18 Given advances in measles control programmes, which mean that infants now receive less MMAs from their mothers, 18,21 our study findings (at three and six months) were anticipated.
In our study, at nine months of age, almost all of the enrolled subjects were unprotected against measles. Only 5.2% of them had protective levels of MMAs. This is consistent with the finding of a study that was conducted in France. 22
However, none of the infants who were studied in South Africa had protective levels of MMAs at nine months of age. 23 The reason for this could be a physiological saving mechanism that was present in the infants. 24 It is believed that high levels of MMAs at birth are eliminated rapidly, whereas low levels of MMAs at birth are saved so that they last longer in infancy. 24 Therefore, there was an increased susceptibility to measles in the current study population. In the present study, the loss of MMAs was independent of the gender of the infants, which corroborated observations that have been made by other researchers. 15 Also, in the current study, the decline of MMAs was independent of the gestational age of the infants. Although sample sizes in relation to gestational ages were small in our study and may not be of sufficient power, the findings agree with the observations of a study that was conducted in Atlanta, Georgia. 15 Gestational age could be a factor that influences MMAs at birth, rather than the waning of MMAs in infancy.
In conclusion, our findings suggest that there were protective levels of MMAs in newborn infants at birth. These levels rapidly declined in infancy, irrespective of gender and gestational age at birth. The majority of the infants were unprotected against measles by the age of six months. Together with ample evidence for a high disease burden in susceptible infants, our findings suggest that new, safe and effective measles vaccines to protect these infants should be introduced. A large population-based sero-survey at community level is also needed in Nigeria to further validate this study of public health significance.
